Compare ACM Research Inc (ACMR) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACM Research Inc vs Merck & Co., Inc. — how do they compare? ACM Research Inc trades at $80.55 (market cap $5.57B), while Merck & Co., Inc. trades at $132.72 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 57.8× ACM Research Inc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while ACM Research Inc pays none. Which is the better fit depends on your goals.
| ACMR | MRK | |
|---|---|---|
Market Cap | $5.57B | $321.77B |
Sector | Technology | Health |
52-Week High | $126.89 | $132.93 |
52-Week Low | $25.02 | $77.60 |
Enterprise Value | $4.48B | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACMR trades at $81.26, up 2.33% today, with a neutral technical signal and bearish moving averages. The stock shows strong fundamentals with Q2 2026 EPS beating estimates at $0.61 versus $0.42 expected, revenue growth of 36% year-over-year to $292.9 million, and raised 2026 guidance. Net income margin improved to 14.48% in 2026 from 10.43% in 2025, supported by robust orders and product expansion.
Outlook remains positive with an 80% analyst buy rating and consensus price target of $127.50, implying significant upside. Risks include high P/E of 37.7, negative operating cash flow, and semiconductor cycle volatility. Growth catalysts are new wet processing platforms and overseas expansion, but execution on guidance is critical.
Merck (MRK) trades at $130.45, down 0.34% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, net income was $18.25B, and the P/E ratio stands at 104.34. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.
Outlook: Merck's acquisition strategy and consistent dividend payments ($0.85 per share) support a positive view, with analyst consensus price target at $140.58. Risks include high valuation multiples and competitive pressures in pharmaceuticals. Institutional holdings show increased interest, but investors should monitor integration of acquisitions and patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACM Research Inc
ACM Research develops and manufactures semiconductor process equipment, specializing in wafer cleaning and electroplating solutions. Its tools are used by global chipmakers to improve productivity and yield for logic and memory chips.
Read more on ACMR →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
